Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.
The latest round covers 15 NDCs sold during Q3 2019. The previously announced refunds were for sales during Q1 2019 and Q2 2019. Merck said its recalculated 340B ceiling prices “are the result of revised pricing data that were submitted to the Centers for Medicare & Medicaid Services.” The U.S. Health Resources and Service Administration (HRSA) posted Merck’s notice dated Aug. 19 on its website on Tuesday.
Merck said it will contact entities if they are owed more than $10.00 across all the applicable NDCs. If an entity does not hear from Merck and believes it is owed a refund, Merck said it should contact the company at an email address listed in the notice.
Merck is one of the 18 manufacturers to impose conditions on 340B pricing when covered entities use contract pharmacies.
